SVF
Level A· Stronger Clinical EvidenceSystematic Review

Intra-articular Mesenchymal Stem Cell Therapy for the Human Joint: A Systematic Review.

McIntyre JA., Jones IA., Han B., Vangsness CT.

Systematic Review with a reported sample of 523 on Osteoarthritis, Cartilage Damage, Ankle Injury, published in Am J Sports Med (2018) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Am J Sports Med (2018)
Country
United States
Reported sample size
523
PMID
29099618
DOI
10.1177/0363546517735844

Abstract (original English)

Stem cell therapy is emerging as a potential treatment of osteoarthritis (OA) and chondral defects (CDs). However, there is a great deal of heterogeneity in the literature. The indications for stem cell use, the ideal tissue source, and the preferred outcome measures for stem cell-based treatments have yet to be determined. To provide clinicians with a comprehensive overview of the entire body of the current human literature investigating the safety and efficacy of intra-articular mesenchymal stem cell (MSC) therapy in all joints. To provide a comprehensive overview of the current literature, all clinical studies investigating the safety and efficacy of intra-articular MSC therapy were included. PubMed, MEDLINE, and Cochrane Library databases were searched for published human clinical trials involving the use of MSCs for the treatment of OA and CDs in all joints. A total of 3867 publications were screened. Twenty-eight studies met the criteria to be included in this review. Fourteen studies treating osteoarthritis and 14 studies treating focal chondral defects were included. MSCs originating from bone marrow (13), adipose tissue (12), synovial tissue (2), or peripheral blood (2) were administered to 584 distinct individuals. MSCs were administered into the knee (523 knees), foot/ankle (61), and hip (5). The mean follow-up time was 24.4 months after MSC therapy. All studies repo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Cartilage DiseasesHumansInjections, Intra-ArticularKnee JointMesenchymal Stem Cell TransplantationMesenchymal Stem CellsOsteoarthritis, KneeReproducibility of Results
KneeHipAnkle & FootOsteoarthritisCartilage DamageAnkle Injury
View on PubMedDOI

Related research